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Summary
In the UK, over one-quarter of the adult population have obesity (body mass
index ≥30 kg m−2). This has major implications for patients’ health and the
National Health Service. Despite published studies showing that signiﬁcant weight
loss can be achieved and maintained in primary care, and guidance from the
National Institute for Health and Care Excellence, weight management services
are inconsistently implemented. This may be due primarily to workload and ﬁnan-
cial constraints. There is also a lack of belief that specialist weight management
services and anti-obesity medications (AOMs) are a viable alternative to bariatric
surgery for long-term maintenance of weight loss. This article discusses the chal-
lenges facing obesity management and explores the reasons for the lack of invest-
ment in AOMs in the UK to date. The aim of this article is to identify whether the
newer AOMs, such as naltrexone/bupropion and liraglutide 3.0 mg, are likely to
perform better in a real-world setting than current or withdrawn AOMs. In addi-
tion, it considers whether the equitable provision of specialist weight management
services and future clinical trial design could be improved to help identify those
individuals most likely to beneﬁt from AOMs and, thus, improve outcomes for
people with obesity in the UK.
Keywords: Anti-obesity medications, obesity, weight management.
Introduction
In 2015, the UK had the highest level of obesity in Western
Europe (26.9%), ahead of countries such as France
(15.3%), Germany (23.6%) and Spain (16.7%) (1). The
economic implications are substantial due to both direct
healthcare costs and the loss of productivity and life
years (2).
Although there are guidelines for the prevention and
management of obesity in the UK (3–5) several challenges
present when implementing these in clinical practice. The
foundation of obesity management is diet and exercise,
supported by behaviour change (i.e. lifestyle intervention),
but many people are unable to achieve a clinically mean-
ingful weight loss (deﬁned as ≥5% after 1 year of treatment
(6)) with this approach alone (7). In 2013, the National
Health Service (NHS) Commissioning Board recommended
the introduction of multidisciplinary weight management
services for people with severe and complex obesity,
including for those being considered for bariatric surgery,
which include specialist oversight, training in behaviour
change techniques and psychological support (8). These
services should be made available to people with obesity
for whom lifestyle interventions have not been successful
(8). Many people accessing these multidisciplinary services
report beneﬁts from this level of engagement and ﬁnd that
they are better able to make permanent lifestyle modiﬁca-
tions in ways that lead to improvements in weight (8).
However, the provision of weight management services is
implemented inconsistently across the UK (8). Bariatric sur-
gery is recommended for those with a body mass index
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(BMI) >40 kg m−2 (or above 35 kg m−2 in the presence of
major comorbidity) when all non-surgical measures have
been tried without success, and should be prioritized for
those with a BMI >50 kg m−2 and those with recent-onset
type 2 diabetes (T2D) with a BMI as low as 30 kg m−2 (3).
Whilst it is highly effective, this option is only appropriate
for certain people with obesity, and access is limited (3).
Anti-obesity medications (AOMs) may be prescribed in
primary care, as well as in specialist clinics, as an adjunct
to lifestyle management. However, in recent history two
AOMs have been withdrawn from the market due to safety
concerns (9, 10), and the only remaining AOM that is
widely prescribed (orlistat) has only modest efﬁcacy, and
side effects limit its use for many people with obesity (11,
12). In 2015, the European Medicines Agency (EMA)
approved two additional AOMs, but neither is currently
recommended by the National Institute for Health and
Care Excellence (NICE). This article examines the chal-
lenges facing obesity management in the UK, in particular
why AOMs have not been widely accepted in clinical prac-
tice. It considers whether the newer AOMs are likely to
perform better, and how we can improve current clinical
practice and future clinical trial design to identify those
individuals most likely to beneﬁt from AOMs and, thus,
improve outcomes for people with obesity.
The scale of the obesity epidemic in the UK
In 2015, approximately one-quarter of adults in the UK
had a BMI ≥30 kg m−2, which classes them as having obe-
sity (13–16). The prevalence of severe obesity (BMI ≥40 kg
m−2) in 2015 was approximately 3% (England and Scot-
land) (15, 17). Obesity is associated with almost 200 meta-
bolic, mechanical and mental comorbidities (18), many of
which increase in prevalence as BMI rises (19). The risk of
T2D, for example, rises exponentially with increasing BMI
(20), which, in turn, increases the risk of cardiovascular
(CV), microvascular and other complications (21). In
2012, the annual economic impact of obesity in the UK
was £73 billion (3.0% gross domestic product [GDP]) and
ranked second behind smoking (£90 billion; 3.6% GDP)
(2). A simulated model predicts that by 2030 there could
be an increase in the prevalence of obesity to up to 48% in
men and up to 43% in women, equating to approximately
11 million more people with obesity in the UK (22). Com-
bined medical costs for treatment of the complications of
obesity are estimated to increase each year by up to £2 bil-
lion (22). The prevalence of severe obesity, which is associ-
ated with even greater healthcare costs, is also forecast to
rise (13, 15, 16) (data not available for Northern Ireland);
already over a million people are affected, and bariatric
surgery is offered to less than 1% of this group annually
(23). Projections largely indicate the BMI of people with
overweight or obesity to be increasing over time (22),
reﬂecting the chronic nature of the condition.
Current guidelines for weight management in
adults in the UK
In the UK, people with obesity primarily access weight loss
interventions through primary care services (24–26) or by
self-referral to commercial slimming organizations. NICE
and the Scottish Intercollegiate Guidelines Network (SIGN)
provide guidance for multicomponent lifestyle weight man-
agement, based on the severity of obesity and the presence
of weight-related comorbidities (3, 5). Multicomponent
lifestyle interventions (which include physical activity, die-
tary changes and behavioural components) should be the
treatment of choice. AOMs should be considered on an
individual case basis, where target weight has not been
achieved through lifestyle interventions. In the UK, the
NHS Commissioning Board recommends a 4-tiered weight
management approach (Fig. 1) (4).
Tier 2 services in the UK
Commercial lifestyle weight management programmes,
such as Rosemary Conley, Slimming World or Weight
Watchers, demonstrate proven effectiveness at 12 months
(27) and should help people with overweight or obesity to
assess their weight and set realistic goals for weight loss,
and support them in achieving it through long-term, steady
weight reductions using a multicomponent approach (28).
In 2013, approximately 69 000 adults in UK were referred
to Weight Watchers and Slimming World under the NHS
schemes (4). Commercial programmes have been shown to
be effective in the short term, with a 12-week programme
achieving approximately 5% body-weight loss (4.8 kg);
however, drop-out rates are high (29). In the longer-term
(12 months), commercial programmes appear to be more
effective than standard of care (i.e. weight loss advice from
a general practitioner [GP]), with participants losing twice
as much weight on the commercial programme (27).
Despite the success of such programmes, for many, there is
signiﬁcant weight regain beyond the end of the programme
(30). For people with a BMI ≥35 kg m−2 with additional
risk factors, or >40 kg m−2 who are unable to achieve last-
ing weight loss through Tier 2 services, referral to Tier
3 weight management services is recommended to provide
more intensive support, pharmacotherapy (if appropriate)
and consideration for subsequent surgical referral (3).
Tier 3 services in the UK
Several programmes have shown that Tier 3 services can be
implemented successfully in primary care and that they
may be more cost-effective than Tier 3 services based in
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secondary care (24). The Scottish Government commis-
sioned three phases of ‘The Counterweight Programme’,
evaluated over 4 years (2001–2004) (31). Interventions
delivered by practice nurses achieved an average weight
loss of 3.0 kg for patients attending at 12 months and
2.3 kg for patients attending at 24 months (31). Over 30%
of attendees maintained a weight loss of ≥5% at 12 months
and at 24 months (31). This study demonstrated that, with
the appropriate training and support, clinically signiﬁcant
weight loss can be achieved and maintained in primary care
(31). The Rotherham Institute for Obesity (RIO), one of
the ﬁrst GP-led services delivered in primary care, was initi-
ated in 2010 and funded by Public Health Rotherham (26).
It offered multidisciplinary services in primary care for peo-
ple with a BMI ≥30 kg m−2 with additional risk factors, or
>40 kg m−2 not achieving NHS Rotherham weight loss tar-
gets with Tier 2 support services (32). During the 2-year
period from 2010 to 2011, 66% of people completing the
RIO programme met or exceeded weight loss targets (26).
Of these successes, 72% of participants lost >5% of initial
body weight and 19% of participants lost >10% (26). In
2017, Public Health Rotherham decommissioned RIO after
8 years (33). The Fakenham Weight Management Service
(FWMS) was modelled on RIO and offered a 1-year pri-
mary care programme to support weight loss through the
implementation of sustainable lifestyle changes (24). The
service (which reported on participants enrolled from
August 2011 to August 2012) was evaluated using the
National Obesity Observatory Standard Evaluation Frame-
work (NOO SEF) and 117 of the 170 participants com-
pleted the programme (24). Of the ‘completers’, 72.6%
had lost ≥5% of their initial body weight (24). In Liver-
pool, the Aintree Liverpool Obesity Support Service
(LOSS) programme provides community-based, multidisci-
plinary support for people with severe and complex obesity
(average BMI 45.6 kg m−2) in a community setting (34).
During the 4-year period from 2009 to 2013, 2472 people
were referred to the service; a retrospective follow-up of
2315 appropriate referrals showed that, of those who
engaged with the programme, over one-third attending for
longer than 6 months achieved a weight loss of more than
5% (34). This study also highlighted the difﬁculty in main-
taining engagement, especially in younger individuals from
areas of high socioeconomic deprivation (34). Despite the
successes, there is evidence to suggest that Tier 3 services
are often poorly implemented or lacking in some areas of
the UK, with substantial regional variation (8, 35).
Challenges associated with long-term
maintenance of weight loss
There are several reasons why a large proportion of people
with obesity are unable to achieve long-lasting weight loss.
Following weight loss, the body compensates through
Figure 1 The 4-tiered weight management approach recommended by the UK NHS commissioning board. AOM, anti-obesity medication; GP, General
Practitioner; NHS, National Health Service. Adapted from Commissioning guide 2014. Weight assessment and management (Tier 3). BOMSS,
RCS, NICE.
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several counter-regulatory mechanisms that involve periph-
eral and central modulators of appetite and energy expen-
diture (36). Circulating concentrations of leptin, glucagon-
like peptide-1, peptide-YY and amylin decrease, impairing
satiety, whereas plasma ghrelin levels increase, driving hun-
ger (37–42). In addition, weight loss is associated with
slowing of metabolic rate that contributes to weight regain
and progresses over time (7). Furthermore, it is difﬁcult to
maintain weight loss in the presence of strong environmen-
tal pressures that contributed to weight gain in the ﬁrst
place, e.g., easily accessible fast food outlets, or lack of
cycling infrastructure (43).
Anti-obesity medications
The increasing prevalence of obesity in the UK and the
understanding that many individuals may be unable to
achieve and maintain weight loss with lifestyle interven-
tions alone mean that the addition of newer AOMs to obe-
sity management has become a more urgent priority.
Orlistat (usual dose 120 mg three times daily [TDS] with
meals) is currently the only AOM approved for long-term
use in the UK and recommended by NICE (44) (Table 1).
Orlistat inhibits pancreatic lipase and reduces fat absorp-
tion in the gut (44). Orlistat should be stopped after
12 weeks if an individual has been unable to lose ≥5% of
their body weight from start of treatment (44). Orlistat at a
lower dose of 60 mg TDS is available over-the-counter in
the UK and is indicated for weight loss in adults who are
overweight (BMI ≥28 kg m−2), in combination with a
mildly hypocaloric, lower-fat diet (47). Sibutramine, a
serotonin-noradrenaline re-uptake inhibitor, was available
in the UK; however, post-approval data showing a higher-
than-anticipated incidence of CV adverse events (AEs)
(e.g. myocardial infarction, stroke and cardiac arrest) in
participants at high risk of CV disease led to withdrawal of
its marketing authorization by the EMA in 2010 (10).
Rimonabant, a cannabinoid receptor 1 blocker, was avail-
able in the UK from 2006; however, post-approval data
showing serious psychiatric AEs led to its withdrawal in
2008 (48).
A greater understanding of energy homeostasis and cen-
tral appetite regulation has led to the development and
recent regulatory approval of four other AOMs (Table 1).
Naltrexone/bupropion (8.0 mg/90 mg two tablets twice
daily [BID]) and liraglutide (3.0 mg once daily [OD] by
subcutaneous injection) are approved for the long-term
treatment of obesity in both Europe and the US; both are
subjected to additional monitoring for AEs (49, 50).
Although naltrexone/bupropion and liraglutide 3.0 mg are
approved by the EMA, neither drug has been recom-
mended by NICE. In July 2017, NICE issued a ﬁnal
appraisal determination for naltrexone/bupropion, which
did not recommend its use in the UK due to uncertainty
over long-term effectiveness and value for the NHS (51).
The other two AOMs have been approved for long-term
treatment by the US Food and Drug Administration (FDA),
but are not approved in Europe; they are phentermine/
topiramate extended release (ER) (3.75 mg/23 mg;
7.5 mg/46 mg; 11.25 mg/69 mg; 15 mg/92 mg OD) and
lorcaserin (10 mg BID). In 2012, the Committee for Medic-
inal Products for Human Use (CHMP) concluded that the
beneﬁts of phentermine/topiramate did not outweigh its
risks (due to concerns over the long-term effects on the
heart and blood vessels, long-term psychiatric effects, cog-
nitive effects, teratogenicity and also that it would not be
strictly used for the intended people) and recommended
that it be refused marketing authorization (52). In February
2013, the CHMP reviewed the data for lorcaserin and had
some concerns regarding the risk of tumours with long-
term use (based on non-clinical studies) and the potential
risk of psychiatric disorders and valvulopathy (53). Three
months later, the manufacturers of lorcaserin notiﬁed the
CHMP that they wished to withdraw their application for
marketing authorization (53).
How AOMs have translated into clinical
practice to date: the efﬁcacy–
effectiveness gap
Despite the availability of AOMs in the UK, evidence sug-
gests that they have not lived up to the promise shown in
clinical trial programmes. Orlistat and sibutramine (when
it was available) appear to be much less effective in general
practice than in randomized clinical trials (54, 55). A retro-
spective analysis of data from the UK Clinical Practice
Research Datalink (CPRD) in 2014 (that identiﬁed
100 701 people receiving orlistat, 15 355 receiving sibutra-
mine and 508 140 receiving no intervention) showed that
in UK clinical practice, orlistat and sibutramine had early
effects on weight loss, but that these were not sustained
over a 3-year period (11). Findings from the CPRD suggest
that treatment courses of orlistat are generally longer in
clinical trials than in clinical practice, with 28% of people
in the UK receiving only a single prescription (indicating
that they received little or no treatment) (11). Prescribing
records in the UK indicate that 2 years after initiating orli-
stat therapy, the median proportion of follow-up is only
11% compared with approximately 50% in clinical tri-
als (11).
With any medicine, there is a gap between the efﬁcacy of
an intervention under ideal clinical trial conditions and the
effectiveness when it reaches clinical practice (56). The
efﬁcacy–effectiveness gap arises due to biological and beha-
vioural variations in the real-world setting compared with
a clinical trial setting. The extent of this gap is dependent
on the external validity of the clinical trial (56). Important
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components that contribute to external validity include:
trial setting, patient recruitment, baseline characteristics,
differences between the trial protocol and routine clinical
practice and AE reporting (56, 57).
Recruitment of individuals to randomized clinical trials
is carefully controlled via inclusion and exclusion criteria,
resulting in a relatively homogeneous population under
evaluation. Treatment with the drug under evaluation is
optimized so that efﬁcacy tends to be high and susceptibil-
ity to AEs low (56). Common limitations in phase 3 trials
in obesity are that they recruit a population of mainly
middle-aged, Caucasian women with few comorbidities
(58). As someone who works in Tier 3 services, I have
observed that some sub-populations are under-represented
in trials of AOMs, e.g. older adults or individuals with
BMI >50 kg m−2, T2D, obstructive sleep apnoea (OSA) or
mobility issues. This means that the efﬁcacy and safety
ﬁndings from trials of AOMs may not be generalizable to a
large proportion of the people who are seen in Tier 3 ser-
vices or, indeed, to many other people with obesity in the
UK (58). In 2010, this was the case with a post-approval
analysis from the Sibutramine Cardiovascular Outcomes
Table 1 Overview of the AOMs currently approved for use in US/Europe (45, 46)
AOM Indication MoA Stopping rule Approval status NICE status UK (NHS)
Orlistat
60 mg (OTC) or
120 mg (Rx)
Adjunct to a reduced-
calorie diet in
1. obese BMI
≥30 kg m−2
2. overweight BMI
≥28 kg m−2 with
comorbidities
Lipase inhibitor Europe: Discontinue after
12 weeks if individual
has been unable to lose
≥5% of initial BW
Europe:
Approved
(Rx & OTC)
(1998/2007)
US: Approved
(Rx & OTC)
(1999/2007)
Recommended Available
PHEN/TPM ER
3.75 mg/23 mg
7.5 mg/46 mg
11.25 mg/69 mg
15 mg/92 mg
Adjunct to diet and
physical activity for
chronic weight
management in:
1. obese BMI
≥30 kg m−2 and
2. overweight BMI
≥27 kg m−2 with
comorbidity
NA and DA
reuptake
inhibitor and
glutamate RA
Discontinue if ≥5% BW
loss is not achieved
after 12 weeks on
maximum dose
Europe:
Rejected
(2013)
US: Approved
(2012)
N/A Not available
Lorcaserin
10 mg
Selective 5-HT2c
RA
Discontinue if the
individual has not lost
≥5% of baseline BW by
week 12
Europe:
Application
withdrawn
(2013)
US: Approved
(2012)
N/A Not available
Naltrexone/
bupropion
8.0 mg/90 mg
μ-opioid RA/NA
and DA
reuptake
inhibitor
Europe: Discontinue after
16 weeks if individual
has not lost ≥5% of their
initial BW
US: Discontinue if
individual has not lost
≥5% of their baseline
BW after 12 weeks of
treatment at the
maintenance dosage
Europe:
Approved
(2015)
US: Approved
(2014)
Not recommended Not available
Liraglutide
3.0 mg
GLP-1RA Europe: Discontinue if
individual has not lost
≥5% initial BW loss after
12 weeks of treatment
on the 3.0 mg day−1
dose
US: Discontinue if the
individual has not lost
≥4% of baseline BW
16 weeks after
treatment initiation
Europe:
Approved
(2015)
US: Approved
(2014)
Not reviewed to date;
review by NICE to
be determined
Availability via
the NHS yet to
be determined
5-HT, serotonin; AE, adverse event; AOM, anti-obesity medication; BMI, body mass index; BW, body weight; DA, dopamine; EMA, European Medicines
Agency; ER, extended release; FAD, ﬁnal appraisal determination; GLP-1RA, glucagon-like peptide-1 receptor agonist; MoA, mechanism of action; NA,
noradrenaline; N/A, not applicable; NHS, National Health Service; NICE, National Institute for Health and Care Excellence; OTC, over-the-counter; PHEN,
phentermine; RA, receptor antagonist; Rx, prescription; TPM, topiramate.
© 2018 The Authors. Clinical Obesity published by John Wiley & Sons Ltd
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Trial (SCOUT); data suggested an increased risk of stroke
and myocardial infarction compared with placebo (59).
The indications for approved AOMs include people with
overweight (BMI ≥27 kg m−2) with comorbidities
(Table 1), which means people receiving AOMs in clinical
practice may differ signiﬁcantly from those who participate
in clinical trials.
Clinical trial infrastructure is such that participants
receive regular contact with a multidisciplinary team, and
have health-related quality of life and symptoms of depres-
sion monitored at regular intervals. In an ideal world, care
in UK clinical practice should aim to reﬂect the approach
used in clinical trials. Whilst we have examples of where
this is possible (e.g. RIO, FWMS, Aintree LOSS (24, 26,
34)), there is substantial regional variation in the provision
of dietary advice, education (on obesity risk factors, life-
style factors, obesity-related health risks and weight loss
options) and psychological support. The transfer of public
health services from Primary Care Trusts to Local Authori-
ties in 2013 resulted in further disruption to services (8).
There has been a recurring pattern of early promise and
late failure in the clinical development of AOMs (60), and
most AOMs developed to date have either not received reg-
ulatory approval or have been withdrawn from the market
due to unacceptable side effects (60). It is perhaps then no
surprise to primary care practitioners that the UK currently
has only one NICE-recommended prescription AOM and
that commissioning bodies are reluctant to invest (or may
even be disinvesting) in specialist Tier 3 support services.
Will the recently approved AOMs change
weight management practice in the UK?
Building on previous experience
By identifying reasons for the suboptimal translation of
current AOMs to clinical practice, we are able to assess if
the more recently approved AOMs will fare any better and
what clinicians can do to facilitate improved outcomes for
people with obesity. Based on a review of the phase 3 ran-
domized clinical trials of naltrexone/bupropion, liraglutide
3.0 mg and orlistat 120 mg, the following factors may
inﬂuence the efﬁcacy–effectiveness gap in the UK.
Individuals with obesity and comorbidities
The phase 3 trials of naltrexone/bupropion and liraglutide
3.0 mg (Table 2) have gone some way to addressing the
efﬁcacy–effectiveness gap with regard to people with obe-
sity and comorbidities by evaluating the efﬁcacy of naltrex-
one/bupropion in people with obesity and T2D and of
liraglutide 3.0 mg in people with obesity and prediabetes,
T2D or OSA. However, a gap still exists between the dis-
ease stage of people taking part in randomized clinical tri-
als and those in a Tier 3 clinical practice setting. Those in
Tier 3 typically have severe obesity, have accumulated a
large number of comorbidities (34) and found that Tier
2 support is not sufﬁcient. The cost-effectiveness models
used by NICE are based on phase 3 data and a limited set
of outcomes, so may not fully take into account the beneﬁ-
cial effects of weight loss in cases of people with severe obe-
sity with multiple complications.
Responders versus non-responders
The prescribing rules for AOMs require an evaluation of
response after 12 weeks at the intended clinical dose (after
any titration period). Individuals who have not lost ≥5% of
baseline weight after 12 weeks of intended clinical dose are
considered ‘non-responders’ and the treatment should be
stopped (according to the EMA stopping rule), whereas
individuals achieving this clinically meaningful weight loss
target after 12 weeks at intended clinical dose are consid-
ered ‘responders’. For example, in the Satiety and Clinical
Adiposity – Liraglutide Evidence (SCALE) in individuals
with and without diabetes Obesity and Prediabetes trial,
the proportion of all subjects (responders and non-
responders) achieving a ≥5% weight loss at week 56 with
liraglutide 3.0 mg was 63.2% (versus 27.1% with placebo)
but was 88.2% for responders (versus 36.9% for non-
responders) (68). This type of analysis may better describe
the likely real-world effectiveness, assuming the stopping
rule is followed.
Reduction of risk factors
In the phase 3 trials of naltrexone/bupropion, liraglutide
3.0 mg and orlistat 120 mg (Table 2) there was evidence of
the broader clinical beneﬁt of AOMs. XENDOS (XENical
in the prevention of Diabetes in Obese Subjects) study data
show that 4 years of orlistat treatment confers a statisti-
cally signiﬁcant improvement in waist circumference, dia-
stolic and systolic blood pressure, fasting plasma glucose
(FPG) and total cholesterol versus placebo (55). COR-I
(CONTRAVE Obesity Research I) data show that
56 weeks of naltrexone/bupropion treatment confers a sta-
tistically signiﬁcant improvement in FPG levels, fasting
insulin and insulin resistance versus placebo (58). SCALE
Obesity and Prediabetes study data show that responders
completing 56 weeks of treatment with liraglutide 3.0 mg
experience a greater reduction in glycated haemoglobin
(HbA1c), FPG, systolic and diastolic blood pressure, and
that all measures of fasting lipids, high-sensitivity C-
reactive protein, plasminogen activator inhibitor-1 and adi-
ponectin were improved versus placebo (63). Furthermore,
an extension of the trial in people with obesity and predia-
betes shows that, while on treatment, more individuals in
the liraglutide 3.0 mg group (970/1472; 66%) had
regressed from prediabetes to normoglycaemia by week
160 than had individuals in the placebo group (268/738;
36%) (64). SCALE Diabetes study data show that
Clinical Obesity 8, 211–225, June 2018 © 2018 The Authors. Clinical Obesity published by John Wiley & Sons Ltd
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56 weeks of liraglutide 3.0 mg treatment signiﬁcantly
improved HbA1c and FPG levels; the proportion of partici-
pants achieving American Diabetes Association (ADA) and
American Association of Clinical Endocrinologists (AACE)
HbA1c target levels was signiﬁcantly greater than with pla-
cebo in people with obesity and T2D. In addition, systolic
blood pressure, lipid proﬁle (total cholesterol, very-low-
density lipoprotein, high-density lipoprotein and triglycer-
ides) and some CV biomarkers (plasminogen activator
inhibitor 1 and urinary albumin to creatinine ratio) were
also improved versus placebo (65). SCALE Sleep Apnoea
study data show that participants in the liraglutide 3.0 mg
group had a signiﬁcantly greater reduction in the number
of apnoea–hypopnoea events/hour at week 32, compared
with the placebo group (67).
As described above, there are a number of factors that
may affect the translation of recently approved AOMs into
UK clinical practice. Yet, we have also seen that there are a
multitude of clinical beneﬁts that could be gained by people
with obesity in addition to weight loss. With this in mind,
what can we do moving forward to reduce the efﬁcacy–
effectiveness gap in the UK and, ultimately, to improve
patient outcomes?
Improving outcomes for people with obesity
in the UK
Given the burden that obesity places on the lives and health
of the people it affects, and the strain that the disease and
its complications place on our healthcare system, it is
important that appropriate interventions are available to
help treat those who are overweight or have obesity. With
the prevalence of obesity predicted to continue to rise (22),
there is also a need to make environmental changes to
lessen the future epidemic. Key aspects that could reduce
the efﬁcacy–effectiveness gap include applying best practice
to ensure equitable access to all four tiers of obesity care
(from prevention through to bariatric surgery) nationwide
(particularly ensuring additional support for those with
more severe and complicated obesity in Tier 3 services),
and undertaking real-world effectiveness trials to help opti-
mize the use of currently available AOMs. This may offer
cost-effective implementation within the NHS, particularly
for individuals who may beneﬁt, thereby closing the
efﬁcacy–effectiveness gap.
Driving improvements in the provision of Tier
3 support services
There are exemplary cases where Tier 3 services and
commissioning guideline recommendations have been
implemented, but these need to be applied consistently
throughout the UK to address a number of key barriers.
These include the belief (by both people with obesity andTa
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commissioners) that medical therapy is not effective, con-
straints on medical workloads, a lack of trained staff,
ﬁnancial constraints and the challenges of NICE evaluation
(8). Moreover, some commissioners believe that Tier 3 ser-
vices are simply a bridge to bariatric surgery and that suc-
cessfully achieving weight loss with AOMs (without the
need for bariatric surgery) is unlikely (8). More needs to be
done to improve the efﬁciency of Tier 3 services,
e.g. through partnerships with other NHS schemes or com-
mercial organizations and the use of health trainers and
group sessions. These services should, however, be tailored
to the complex needs of people with obesity who have had
multiple failures to maintain weight loss with Tier 2 sup-
port. The NOO SEF recommends Tier 3 services collect
data on diet, physical activity and quality of life in addition
to demographic data (69), but this requires dedicated
administrators and a large database. The NOO SEF does
not recognize important changes such as HbA1c in people
with T2D (69), yet additional clinical outcomes, including
psychological outcomes and quality of life, should be
reported to reﬂect the clinical and economic gains over and
above weight loss that are provided by AOMs. These out-
comes can be built into clinical systems (as has been done
e.g. with the National Diabetes Audit – NHS Digital (70))
and used to drive improvements in care forward. Partner-
ships with academic centres to improve robust data collec-
tion would help teams demonstrate the value of Tier
3 services to the NHS (8).
Support for people with signiﬁcant comorbidity
The medical costs for people with T2D are greater than for
those without, and increase with every additional kg m−2
of BMI (71). For people with severe obesity this difference
amounts to thousands of pounds per year (70). In 2016,
the NHS began to roll out a Diabetes Prevention Pro-
gramme (NHS DPP) (72). By 2020, up to 100 000 places
are to be made available for people at high risk of T2D
(just 1% of the 10 million at risk) to receive personalized
support to reduce their risk, including education on healthy
eating and lifestyle, help to lose weight and bespoke physi-
cal exercise programmes (72). In 2017, a translational
research study of 166 people referred to Weight Watchers
via the NHS DPP showed that after 1 year the mean weight
reduction was 3.2 kg m−2, and 38% individuals returned
to normoglycaemia (73). Health Survey for England (HSE)
data suggest that some people with obesity and non-
diabetic hyperglycaemia (HbA1c: 42.0–47.0 mmol mol
−1
or FPG: 5.5–6.9 mmol L−1) would be eligible to access
NHS DPP support services (in addition to Tier 3 services
for those with BMI >40 kg m−2) (74). If this were success-
ful in preventing people with obesity from developing T2D,
it may help to reduce the burden on the healthcare econ-
omy over the longer term.
Optimizing the use of AOMs
It is clear that some gaps exist in terms of efﬁcacy in clinical
trials versus effectiveness in UK clinical practice, and there
are also concerns about safety, based on previously with-
drawn AOMs. However, AOMs offer a number of clinical
beneﬁts to people with obesity (including reductions in
waist circumference, diastolic and systolic blood pressure,
FPG and total cholesterol) (55, 58, 61–63, 65–67). Based
on evidence from the CPRD regarding orlistat 120 mg, the
shorter treatment duration that was seen in clinical practice
compared with clinical trials may contribute to the
efﬁcacy–effectiveness gap (11). Four AOMs have demon-
strated greater weight loss than lifestyle interventions in
clinical trials, and importantly, aid in the long-term mainte-
nance of weight loss afterwards (55, 58, 61–63, 65–67).
Liraglutide 3.0 mg has published clinical trial data support-
ing efﬁcacy for people with obesity and prediabetes up to
3 years (64). Use of these AOMs also reduces obesity-
associated risk factors, including onset of T2D, dyslipidae-
mia and hypertension (55, 58, 61–63, 65–67). Further-
more, the more encompassing design of clinical trial
programmes such as SCALE suggest that the more recently
approved AOMs may go some way to addressing the
efﬁcacy–effectiveness gap.
Previous experience might give cause for concern
about the safety of AOMs once they enter clinical prac-
tice; however, a post hoc analysis of the SCOUT trial
data suggested that the excess of AEs with sibutramine
occurred in non-responders who continued the drug to
the end of the clinical trial period (75). In clinical prac-
tice, the Summary of Product Characteristics for each of
the current EMA-approved AOMs include the stopping
rule (Table 1), meaning that non-responders should not
continue taking the drug. Consideration should be given
to how best these medications can be employed to opti-
mize outcomes for people with obesity whilst bearing in
mind cost-effectiveness, and key to this is to identify
populations of people with obesity who will respond well
to therapy.
Moving forward, robust real-world evidence studies are
needed to accurately assess the effectiveness of targeted
approaches to weight management. Using an example from
T2D, the Diabetes REmission Clinical Trial (DiRECT) has
successfully demonstrated that the beneﬁts of a structured
weight management programme can be achieved in a real-
world primary care setting at 12 months, with longer term
data awaited (76). For obesity, a phase 4 clinical trial
(STRIVE; NCT03036800) is currently underway to assess
the weight loss (≥15% at 52 weeks; primary outcome),
improvement in obesity-related comorbidities, long-term
cost-effectiveness and budget impact of specialist Tier 3 care
and targeted AOM use in 400 people with severe and com-
plex obesity in the UK.
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The future landscape of pharmacological
weight loss interventions in the UK
Addressing the key aspects above, in order to reduce the
efﬁcacy–effectiveness gap of AOMs in the UK, will be challeng-
ing. Naltrexone/bupropion and liraglutide 3.0 mg have gone
some way to changing the perception of, and building conﬁ-
dence in, the use of AOMs. Several promising new AOMs cur-
rently under evaluation (semaglutide [NCT02453711],
exenatide extended-release [NCT02794402] and the dual
GLP-1/glucagon receptor (GCGR) agonist SAR425899
[NCT03414736]) are predicted to show even greater efﬁcacy
than currently approved AOMs (77). It is possible that new
AOMs may lead to improved clinical outcomes and, ulti-
mately, to a further step change in the perception of AOMs
and acceptance of their use as cost-effective adjuncts to life-
style intervention for some people with obesity. However,
while changing perceptions and increasing acceptance of
AOMs is an important step, other challenges remain.
Without a robust economic analysis that demonstrates
cost-effectiveness and impact on body-weight-related dis-
ease burden, currently approved and new AOMs will not
ﬁt within the NICE model. If we can provide appropriate
and long-term support for people with overweight and obe-
sity in the UK (relative to their BMI and degree of comor-
bidity), broaden the eligibility criteria for clinical trials so
that the data generated more accurately represent the peo-
ple we treat on a daily basis, and identify subgroups of peo-
ple with obesity most likely to beneﬁt from AOMs, we can
start to close the efﬁcacy–effectiveness gap and to change
the treatment landscape in the UK.
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